European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 23 · Tue 17 Nov 

Trials

NCT07412756

ClinicalTrials.gov

Trial ID
T-ctgov-NCT07412756
Registry
ClinicalTrials.gov
NCT number
NCT07412756
CTIS number
2025-522308-25-00
Asset
brenipatide (LY3537031)
Sponsor, as registered
Eli Lilly and Company
Phase
PHASE3
Indication
Depressive Disorder, Major
Status
RECRUITING
Start date
2026-02-09
Primary completion
2028-02
Registered countries
Australia, Brazil, Canada, China, Germany, Greece, Japan, Mexico, Poland, Puerto Rico, South Korea, Spain, Taiwan, United Kingdom, United States
Sites
180

The sponsor's registered location list, which states intent rather than approval.

clinicaltrials.govctgov registryverified 2026-11-07

Notes on the record

Supersedes the row verified 2026-10-19 (kept), per DATA LAYER rule 4. Read live from the ClinicalTrials.gov v2 API 2026-11-07 (https://clinicaltrials.gov/api/v2/studies/NCT07412756); record last update posted 2026-11-04. site_count 181 to 180 location entries; status, dates and the fifteen countries unchanged (DE, GR, PL, ES, UK all still listed). Flagged by the collector (inbox/2026-11-05.json); collector proposal replaced by this live read.

Company

Through brenipatide (LY3537031): Lilly

Cited in

Issues quoting NCT07412756 in their own text.

Record history